✨ Free AI Report
Johnson & Johnson: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Johnson & Johnson
Company Research

Johnson & Johnson: Business Overview, Financials & Competitive Analysis

Johnson & Johnson scores 8/10 on the AskCyborg Cyborg Score (Strong). Diversified exposure across Innovative Medicine and MedTech with momentum from oncology, immunology, and cardiovascular platforms supports mid-single-digit growth trajectory. Johnson & Johnson reported 7.1% quarterly operational sales growth with accelerated momentum in both Innovative Medicine and MedTech segments. The company forecast 2026 operational sales of $99.5 billion to $100.5.

What is Johnson & Johnson's industry? Johnson & Johnson (jnj.com) operates in Pharmaceuticals & Medical Devices (Healthcare/Life Sciences). AskCyborg classifies Johnson & Johnson under Pharmaceuticals & Medical Devices (Healthcare/Life Sciences) in its company registry.

Johnson & Johnson achieved full-year 2025 revenue of $94.2 billion with accelerated momentum in both Innovative Medicine and MedTech segments. CEO Joaquin Duato described 2025 as a catapult year fueled by the stronges...

8/ 10Strong

Cyborg Score thesis

Diversified exposure across Innovative Medicine and MedTech with momentum from oncology, immunology, and cardiovascular platforms...

Read the full analyst-debate transcript →
Industry Pharmaceuticals & Medical Devices (Healthcare/Life Sciences)
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Johnson & Johnson Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Johnson & Johnson

AskCyborg analysts argue the bull and bear cases for Johnson & Johnson across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Johnson & Johnson OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Johnson & Johnson Overview

Pro stress-test →

Johnson & Johnson achieved full-year 2025 revenue of $94.2 billion with accelerated momentum in both Innovative Medicine and MedTech segments. CEO Joaquin Duato described 2025 as a catapult year fueled by the strongest portfolio and pipeline in company history, driven by medical innovation across oncology, immunology, neuroscience, cardiovascular, surgery, and vision.

Strategic Profile

Pro stress-test →

J&J has double-digit growth potential by decade's end, underpinned by a diversified base of 28 billion-dollar products and rapid expansion in oncology, immunology, and cardiovascular markets. The company recently announced its 63rd consecutive annual dividend increase, maintaining its prestigious title as a Dividend King.

Competitive Landscape

Pro stress-test →

J&J operates across oncology, immunology, neuroscience in Innovative Medicine, and cardiovascular, surgery, and vision in MedTech. Primary competitors include pharmaceutical giants like Pfizer, Merck, and AbbVie in the drug segment, and Medtronic, Abbott, and Boston Scientific in medical devices.

Industry Context

Johnson & Johnson operates in Pharmaceuticals & Medical Devices (Healthcare/Life Sciences).

Key facts

Founded: 1886 · Headquarters: New Brunswick, US · Employees: ~135,000 · Revenue: $94.2B · Market cap: ~$450B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Johnson & Johnson.

  • Significant pipeline innovation includes approvals of CAPLYTA for major depressive disorder and RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer, with landmark data for TECVAYLI plus DARZALEX FASPRO as potential standard of care
  • Company invested $32 billion in R&D and M&A during 2025, including strategic acquisitions of Intra-Cellular Therapies and Halda Therapeutics
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026OMNY-AF pilot demonstrates 90% effectiveness at 12 months, strengthening pulsed-field ablation market position
  • January 2026Issued 2026 guidance with $100.5 billion sales and $11.53 adjusted EPS at midpoint, exceeding analyst expectations
  • +2 moreTrack every material event for Johnson & Johnson as it happens. Explore monitoring →
Get alerted when Johnson & Johnson has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Innovative MedicinesCompeting pharmaceutical innovator across oncology and immunology→Merck MedicinesLeading pharmaceutical competitor in oncology and vaccines→Medical DevicesMajor competitor in cardiovascular and surgical device markets→AbbVie MedicinesPharmaceutical competitor focusing on immunology and oncology→

Compare Johnson & Johnson with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Johnson & Johnson operates in Pharmaceuticals & Medical Devices (Healthcare/Life Sciences). See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals & Medical Devices (Healthcare/Life Sciences) research →
NEW · MCP server

Ask your AI assistant about Johnson & Johnson

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Johnson & Johnson and its top competitor on Cyborg Score”
“What did Johnson & Johnson do this quarter?”
“Is Johnson & Johnson a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Johnson & Johnson do?+
Johnson & Johnson achieved full-year 2025 revenue of $94.2 billion with accelerated momentum in both Innovative Medicine and MedTech segments. CEO Joaquin Duato described 2025 as a catapult year fueled by the stronges...
What is Johnson & Johnson's Cyborg Score?+
Johnson & Johnson has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Johnson & Johnson's main competitors?+
Named competitors include Innovative Medicines, Merck Medicines, Medical Devices, AbbVie Medicines. The full competitive landscape is in the AskCyborg report.
How can I get the full Johnson & Johnson research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Johnson & Johnson research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Johnson & Johnson over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.